Aligos Therapeutics preparing $100M IPO (Pending:ALGS

published 27.09.2020 15:27

Image of article 'Aligos Therapeutics preparing $100M IPO (Pending:ALGS'

The lead program, comprised of four candidates, is aimed at a functional cure for chronic hepatitis B virus (HBV) infection.

Another program, with one candidate at present, is focused on NASH, currently preclinical.

by Douglas W. House from seekingalpha.com

Free awesomeness straight to your inbox!

Sign up now for this free newsletter to receive hand picked content, covering topics like Lifestyle, Business & Technology.

Free Newsletter Sign up now!

..or jump directly to the latest posts!